Evaluating the Effectiveness of Prognostic Models in Patients with Cardiogenic Shock Undergoing VA-ECMO Support - Top-Institutions - MDSpire

Evaluating the Effectiveness of Prognostic Models in Patients with Cardiogenic Shock Undergoing VA-ECMO Support

  • By

  • Maria Calvo-Barceló

  • Finn Boyhan Irvine

  • Niamh Tierney

  • Shivani Ayyar

  • Taylor Devine

  • Vasileios Panoulas

  • Maria Montegudo-Vela

  • Fernando Riesgo Gil

  • Clara Hernandez Caballero

  • I. Dolores Poveda Pinedo

  • Javier Bautista

  • Jason Van Schoor

  • Donna Hall

  • Sofia Pinto

  • Eftychia Galiatsou

  • Alex Rosenberg

  • April 28, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Harefield Hospital
    Harefield Hospital

    London, United Kingdom

    Key Differentiators

    • Cardiothoracic Surgery
    • ECMO Programs
    • Critical Care Medicine

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Cardiology
    • Cardiothoracic Surgery
    • Critical Care
    • ECMO Research

  • #3

    University of Michigan Health System
    University of Michigan Health System

    Ann Arbor, Michigan

    Key Differentiators

    • Cardiovascular Medicine
    • Critical Care
    • Mechanical Circulatory Support

  • #4

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Cardiology
    • Cardiothoracic Surgery
    • Critical Care Medicine
    • ECMO

  • #5

    University Hospital Zurich
    University Hospital Zurich

    Zurich, Switzerland

    Key Differentiators

    • Cardiothoracic Surgery
    • Intensive Care Medicine
    • ECMO Research

Original Source(s)

Evaluating the Effectiveness of Prognostic Models in Patients with Cardiogenic Shock Undergoing VA-ECMO Support

  • by Maria Calvo-Barceló, Finn Boyhan Irvine, Niamh Tierney, Shivani Ayyar, Taylor Devine, Vasileios Panoulas, Maria Montegudo-Vela, Fernando Riesgo Gil, Clara Hernandez Caballero, I. Dolores Poveda Pinedo, Javier Bautista, Jason Van Schoor, Donna Hall, Sofia Pinto, Eftychia Galiatsou, Alex Rosenberg

  • April 28, 2026

Related Content

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Residual risk in cardiovascular and renal diseases and the potential role of aldosterone synthase inhibitors

Biomolecular mechanisms of cardiac amyloidosis and its cardiovascular pathological basis